{"id":"W1976585485","doi":"10.1016/s1470-2045(11)70037-7","title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne; Centre hospitalier universitaire de Québec","funders":"","keywords":"Bevacizumab; Metastatic breast cancer; Medicine; Paclitaxel; Placebo; HER2 negative; Oncology; Breast cancer; Internal medicine; Open label; Double blind; Cancer; Clinical trial; Chemotherapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001113102,0.0004666574,0.00225709,0.000167232,0.0002068459,0.00003149945,0.0003538416,0.0001084191,0.001338193],"category_scores_gemma":[0.00009646717,0.0002229247,0.00009697904,0.0003979815,0.0001922852,0.0001326334,0.0000779366,0.0002684081,0.0000202724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00136594,"about_ca_system_score_gemma":0.001431598,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005014015,"about_ca_topic_score_gemma":0.06826907,"domain_scores_codex":[0.9972443,0.0006423866,0.0007176935,0.0005749331,0.0002165869,0.0006041081],"domain_scores_gemma":[0.9968787,0.001775327,0.0004890004,0.0004124888,0.000265416,0.000179101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9069812,0.046675,0.0004682051,0.00008133917,0.003031873,0.000457728,0.007877151,0.00002016007,0.00002432666,0.0001047501,0.0008246223,0.0334536],"study_design_scores_gemma":[0.8684736,0.1220145,0.0002290115,0.0001173801,0.003473298,0.0002400013,0.001521009,0.0009821403,0.0002727495,0.0002755382,0.002163416,0.0002373496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9443246,0.0003429457,0.0001828329,0.01198564,0.0005194629,0.04070152,0.0002566942,0.00007239308,0.001613912],"genre_scores_gemma":[0.9618961,0.001098074,0.001032018,0.0009838972,0.0002992884,0.03160601,0.00009382014,0.00005869367,0.002932071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07533947,"threshold_uncertainty_score":0.9995747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2440107260249871,"score_gpt":0.4720551641385096,"score_spread":0.2280444381135225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}